7 VC firms investing in biotech & life sciences and edtech at the Series B stage.
F4 Fund tracks 7 VC firms that actively invest in biotech & life sciences + edtech at the Series B stage, with check sizes ranging from $100K – $700M (median: $10.1M – $10.1M). As of June 2026, and 100% lead or co-lead rounds. Rankings are based on F4's proprietary analysis of 1,355+ researched VC firms, scored by data completeness, portfolio depth, investment recency, and stage alignment.
| # | Firm | Check Size | Portfolio | Leads? | Activity | Decision | Intro |
|---|---|---|---|---|---|---|---|
| 1 | ▶ Wing Venture Capital The AI-first transformation of business will be as big as digital, mobile, and cloud combined. We invest in companies building the AI-first technology stack: data foundations, AI tools, autonomous applications, and product-led growth companies that accelerate adoption. Founders building at any layer of this stack can reach goals and uncover opportunities previously unattainable. Palo Alto | $200K – $20M | 36 | Leads | Active | ~2 wks | Open |
| 2 | ▶ Binance Labs Support visionary founders building transformative technologies across blockchain, AI, and biotechnology. Provide capital, technical resources, and access to Binance's 300M+ user base and infrastructure. Partner for long-term value creation with founder-centric approach. Cayman Islands | $100K – $5M | 24 | Both | Active | ~2 wks | Open |
| 3 | ▶ Horizons Ventures Invest in deep science and disruptive technology companies that solve fundamental human problems—inequality, health, climate adaptation. We back founders with vision, instinct, and drive to scale impact. Hong Kong | $1M – $25M | 38 | Leads | Active | ~1 mo | Open |
| 4 | ▶ Icehouse Ventures Back exceptional Kiwi founders building globally transformative companies, from day one to IPO. New Zealand founders represent a significantly undervalued asset class, and Icehouse provides capital plus an ecosystem of 3,000+ investors and deep operational support. Auckland | $100K – $10M | 33 | Leads | Active | ~2 mo | Open |
| 5 | ▶ Dalus Capital Back purposeful entrepreneurs building scalable technology solutions for significant Latin American problems, with emphasis on inclusion, climate innovation, and business productivity while generating positive impact and strong returns. Monterrey | $500K – $5M | 29 | Both | Active | ~1 mo | — |
| 6 | ▶ Emerson Collective Emerson Collective invests in entrepreneurs and innovators driven by purpose, seeking consequential companies that deliver both generational impact and venture-scale returns. The firm targets sectors where biggest market opportunities meet meaningful impact levers: energy & environment, digital health, fintech, education, work, and media. Palo Alto | $10M – $700M | 16 | Both | Active | ~1 mo | Req'd |
| 7 | ▶ Gigafund Back the world's most ambitious and transformative entrepreneurs capable of building world-defining companies over 20+ years. Invest in founders with independent thought and first-principles vision to solve humanity's biggest problems across all sectors and geographies. Austin | $1M – $500M | 18 | Leads | Active | 3+ mo | Open |
What other stages do these firms also invest in?
Investors on this page also frequently invest in these sectors
What other sectors do these firms also invest in?
F4 Fund tracks 7 VC firms that actively invest in biotech & life sciences + edtech at the Series B stage. These firms are ranked using a composite score that weighs data completeness (30%), portfolio depth (30%), investment recency (25%), and stage alignment (15%).
Based on F4's analysis, the median check size for series b biotech & life sciences + edtech investors is $10.1M – $10.1M, with a full range from $100K – $700M. The distribution breaks down as: 2 firms in the $2M-$5M range, 1 firms in the $5M-$10M range, 4 firms in the $10M+ range.
Among the 7 firms tracked, 100% lead or co-lead rounds. Founders seeking a lead investor should filter for firms marked "Leads" or "Both" in the rankings table above. Lead investors typically set deal terms and anchor the round.
The best series b biotech & life sciences + edtech investors combine domain expertise with an active portfolio in the space. Among these firms, 17% prefer warm introductions, and the average firm has 28 portfolio companies. Look for firms whose check size matches your raise, whose stage preference aligns with yours, and who have a track record of supporting companies in your sector through multiple growth phases.
Firm profiles are continuously updated through F4's research pipeline, which combines LLM-powered web research, portfolio analysis, and transcript extraction. The ranking data refreshes every 12 hours. Editorial analysis is reviewed weekly. Individual firm profiles are re-researched on a 30-day cycle or when new information surfaces.